NVDA
NVIDIA
-- 149.430 TSLA
Tesla
-- 411.050 FUBO
FuboTV
-- 5.060 PLTR
Palantir
-- 75.920 AMD
Advanced Micro Devices
-- 129.550 
NEWS
ProMIS Neurosciences to Showcase PMN310’s Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences
ProMIS Neurosciences (Nasdaq: PMN) will present preclinical data on its lead product candidate, PMN310, at the 4th International Conference on Cognitive & Behavioral Neurosciences. The data supports PMN310's potential as an Alzheimer's disease treatment, highlighting its enhanced selectivity for toxic amyloid-beta oligomers (AßO). Key findings show:
1. PMN310 demonstrates little to no interaction with monomers
2. It's minimally impacted by excess monomer competition in binding to toxic oligomers
3. PMN310 doesn't bind to Aß plaque or vascular deposits
These characteristics could potentially reduce the risk of amyloid-related imaging abnormalities (ARIA). ProMIS recently reported positive topline data from the first four cohorts in its Phase 1a trial of PMN310, meeting objectives for tolerability, safety, and pharmacokinetics. The company plans to advance PMN310 into a Phase 1b study in Q4 2024.
1. PMN310 demonstrates little to no interaction with monomers
2. It's minimally impacted by excess monomer competition in binding to toxic oligomers
3. PMN310 doesn't bind to Aß plaque or vascular deposits
These characteristics could potentially reduce the risk of amyloid-related imaging abnormalities (ARIA). ProMIS recently reported positive topline data from the first four cohorts in its Phase 1a trial of PMN310, meeting objectives for tolerability, safety, and pharmacokinetics. The company plans to advance PMN310 into a Phase 1b study in Q4 2024.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment